Compare Deckers Outdoor Corp (DECK) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Sana Biotechnology Inc — how do they compare? Deckers Outdoor Corp trades at $82.62 (market cap $10.95B), while Sana Biotechnology Inc trades at $2.79 (market cap $812.76M). The key difference: Deckers Outdoor Corp is far larger — about 13.5× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is more actively traded (4,314,200 versus 3,090,240). Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Sana Biotechnology Inc for 23 Days on average.
| DECK | SANA | |
|---|---|---|
Market Cap | $10.95B | $812.76M |
Volume | 3,090,240 | 4,314,200 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $5.92 |
52-Week Low | $77.51 | $2.68 |
Typical Hold Time | 71 Days | 23 Days |
Enterprise Value | $9.82B | $726.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers Outdoor (DECK) trades at $80.38, down 1.57% today, with strong fundamentals including 19.37% net margin and consistent earnings beats. The stock shows neutral technical signals with support at $78-79 and resistance at $81-82. Revenue growth has accelerated from $3.2B in 2022 to $5.0B in 2025, while profitability metrics remain robust with 42.56% ROE.
DECK presents a compelling value opportunity with attractive valuation multiples (P/E 11.43, EV/EBITDA 7.06) and 46% upside to consensus price target of $117.13. Risks include potential margin pressure from competitive footwear market and projected negative cash flow in 2026. Analyst sentiment leans bullish with 45% buy ratings versus 11% sell recommendations.
SANA Biotechnology trades at $2.72, down 1.09% today, showing bearish technical signals with negative moving averages but oversold RSI readings. The company reported no revenue in 2025 with substantial losses (-$244.17M net income) and negative cash flow (-$55.33M), though analyst sentiment remains positive with 82% buy ratings. Recent investor conference presentations highlight ongoing clinical development activities.
While analyst consensus is bullish with a $9.50 price target (Defense World, July 30, 2026), SANA faces significant fundamental challenges including negative profitability metrics and cash burn. Investment appeal hinges on clinical pipeline success, with risks including execution challenges and the pre-revenue biotech business model requiring continued financing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
